Printer Friendly



1Q Revenues: $3.8 billion (-2%)

1Q Earnings: $430 million (-23%)

Comments: Sales in the U.S. grew 4% to $1.7 billion, while international sales were $2.1 billion, down 6%. Excluding the impact of foreign currency, Baxter's sales grew 4% in the quarter. Baxter's BioScience business generated revenues of $1.4 billion, up 2% driven by immunoglobulin treatments for primary immunodeficiency (PI), hemophilia and inhibitor therapies, and certain bio therapeutics. Medical Products sales were $2.4 billion, down 5%. Excluding foreign currency, sales increased 2%. Results include separation-related costs of $117 million for the planned separation of Baxter's biopharmaceutical and medical products businesses and charges of $18 million related to the integration of Gambro.

COPYRIGHT 2015 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Quarterly Reports
Publication:Contract Pharma
Date:Jun 1, 2015
Previous Article:Lilly.
Next Article:Catalent.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters